CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal Protease Research

Executive Summary: CA-074 Me is a methyl ester derivative of CA-074 that acts as a highly selective, membrane-permeable cathepsin B inhibitor (IC₅₀ = 36.3 nM) [APExBIO]. It achieves 95% inhibition of cathepsin B in human fibroblasts, with complete inhibition under reducing conditions and partial cross-reactivity with cathepsin L. Chemical inhibition of cathepsin B, such as with CA-074 Me, protects cells from necroptosis by blocking lysosomal membrane permeabilization (LMP) (Liu et al., 2024). CA-074 Me enables reliable investigation of apoptosis, necroptosis, and inflammation models in both cellular and in vivo systems. The compound is supplied as a solid and requires proper storage below -20°C for stability.

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in protein catabolism, apoptosis, and regulated necrotic cell death. Lysosomal membrane permeabilization (LMP) releases cathepsin B into the cytosol, triggering proteolytic cascades that lead to cell death (Liu et al., 2024). Among mammalian cathepsins, cathepsin B, D, and L are the most abundant and are implicated in necroptosis and inflammation. MLKL polymerization at the lysosomal membrane is a proximal trigger for LMP, leading to the efflux of active cathepsins [internal]. Chemical inhibition of cathepsin B thus provides a direct method for dissecting the mechanistic steps of lysosome-mediated cell death and cathepsin signaling pathways. This article extends the molecular context established in CA-074 Me: Precision Cathepsin B Inhibitor for Apoptosis by detailing recent advances in MLKL-driven LMP and necroptosis models.

Mechanism of Action of CA-074 Me

CA-074 Me is a methyl ester prodrug of CA-074 designed for membrane permeability. Once inside cells, esterases hydrolyze CA-074 Me to yield the active CA-074 acid, which selectively inhibits cathepsin B by covalent modification of the active site cysteine. The compound exhibits an IC₅₀ of 36.3 nM for cathepsin B in enzymatic assays, with over 95% inhibition in cultured human gingival fibroblasts at effective concentrations. In the presence of reducing agents such as DTT or GSH, CA-074 Me achieves complete inhibition of cathepsin B and partially inhibits cathepsin L (>90% after pre-incubation with reducing agent) [APExBIO]. This selectivity profile distinguishes CA-074 Me from non-specific cysteine protease inhibitors. For further mechanistic comparisons, see Strategic Targeting of Cathepsin B in Lysosomal Cell Death, which focuses on actionable strategies for dissecting LMP pathways, whereas this article details molecular and workflow integration for translational research.

Evidence & Benchmarks

• CA-074 Me achieves 95% inhibition of cathepsin B activity in cultured human gingival fibroblasts at nanomolar concentrations (APExBIO).
• In the presence of 10 mM DTT, CA-074 Me completely inhibits cathepsin B and partially inhibits cathepsin L (>90% after pre-incubation) (APExBIO).
• CA-074 Me is insoluble in water but dissolves in DMSO (≥19.88 mg/mL) and ethanol (≥51.5 mg/mL with ultrasonic treatment) (APExBIO).
• Chemical inhibition or knockdown of cathepsin B protects cells from necroptosis triggered by MLKL polymerization-induced lysosomal membrane permeabilization (Liu et al., 2024).
• In mouse models, CA-074 Me attenuates TNF-α-induced liver injury, demonstrating in vivo efficacy (APExBIO).

Applications, Limits & Misconceptions

CA-074 Me is widely used in research to study the role of cathepsin B in apoptosis, necroptosis, and lysosomal function. It is also employed to investigate cathepsin signaling in pathological contexts such as liver inflammation and cell death models [internal]. This article updates the laboratory challenges and workflow reliability discussed in that resource, by incorporating new mechanistic data from MLKL-driven necroptosis research.

Common Pitfalls or Misconceptions

• CA-074 Me is not water soluble; improper solvent selection can compromise activity.
• Long-term storage of stock solutions above -20°C or repeated freeze-thaw cycles can lead to degradation.
• At high concentrations or under strong reducing conditions, CA-074 Me may partially inhibit cathepsin L, reducing selectivity.
• CA-074 Me does not inhibit all lysosomal cathepsins; results should not be extrapolated to cathepsin D or S.
• The methyl ester form is cell-permeable, but in vivo efficacy depends on metabolic conversion rates and tissue distribution.

Workflow Integration & Parameters

For optimal use, CA-074 Me should be dissolved in DMSO or ethanol and stored at ≤-20°C. Avoid water as a solvent. For cell-based assays, working concentrations typically range from 1–100 μM, with 95% cathepsin B inhibition achieved in fibroblasts at nanomolar levels. Reducing agents such as DTT can enhance inhibition but may also affect selectivity. For animal models, dosing and administration routes must be validated for bioavailability. CA-074 Me is compatible with apoptosis assays, necroptosis induction protocols (e.g., TNF, Smac-mimetic, Z-VAD-FMK), and lysosomal enzyme inhibition studies. For protocol optimization, see CA-074 Me: Unlocking Lysosomal Protease Inhibition in Necroptosis, which presents complementary assay strategies and translational perspectives.

Conclusion & Outlook

CA-074 Me, as provided by APExBIO, is a robust, selective cathepsin B inhibitor enabling precise dissection of lysosomal protease function in cell death pathways. Its documented efficacy in both cellular and animal models supports its use in apoptosis, necroptosis, and inflammation research. Continued development of cathepsin B-targeted inhibitors and refined LMP models will expand the utility of CA-074 Me for mechanistic and translational studies. For detailed specifications and ordering, refer to the official product page: CA-074 Me (SKU A8239).